This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Clive Kearon, MB, FRCPC, PhD; Jack Hirsh, MD, FRCPC

Arch Intern Med. 1993;153(6):700-702.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

ANTITHROMBOTIC properties of aspirin were first proposed 25 years ago when aspirin was shown to inhibit platelet aggregation and to prolong bleeding time,^1-5 but it is only in the past 10 years that the therapeutic benefit of aspirin's antithrombotic properties has been conclusively established by randomized controlled trials.^6-14 Early studies used relatively large aspirin doses of approximately 1000 mg, but with increased understanding of the mechanism of its antithrombotic effect, lower-dose regimens were evaluated and were shown to be as effective with less gastrointestinal side effects.^7,15,16 Antithrombotic benefit from aspirin has been demonstrated with as little as 75 mg/d for unstable angina,⁸ 160 mg/d for acute myocardial infarction,¹⁷ 100 mg/d for aortocoronary grafts,^18,19 and probably as little as 30 mg/d for minor cerebral ischemic events.¹⁶

The trend to use low doses of aspirin increases compliance and reduces gastrointestinal side effects but has the potential . . . [Full Text PDF of this Article]

Author Affiliations
Hamilton Civic Hospitals Research Center and McMaster University Henderson General Hospital 711 Concession St Hamilton, Ontario, Canada L8V 1C3

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?